Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International : Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo

06/14/2021 | 08:26am EDT

DUBLIN - Endo International plc (NASDAQ: ENDP) announced that the Tennessee Court of Appeals recently issued several orders with respect to a default judgment order on liability entered by the Circuit Court for Sullivan County, Tennessee in April 2021 against its wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. (collectively, 'Endo') in Case No. C-41916, originally captioned as Staubus, et al. v. Purdue Pharma, L.P., et al.

Specifically, on June 8, 2021, the Tennessee Court of Appeals declined to review the default judgment order on a discretionary basis on the ground that a contempt judgment becomes final upon the entry of punishment and is immediately appealable as of right. Today, the Tennessee Court of Appeals denied without prejudice the plaintiffs' motion to dismiss Endo's separate appeal as of right from the default judgment order and directed Endo to show cause as to why its appeal should not be dismissed on the procedural ground that portions of the default judgment order were not final. The Tennessee Court of Appeals also denied without prejudice Endo's motion to stay further proceedings in the trial court on the procedural ground that Endo must first seek a stay from the trial court.

Matthew J. Maletta, Endo's Executive Vice President and Chief Legal Officer, commented: 'As we previously stated, Endo believes the trial court's default judgment order was procedurally, factually and legally deficient. We therefore promptly appealed that order to the Tennessee Court of Appeals. The orders issued today by the Tennessee Court of Appeals do not dispose of Endo's appeal as of right. We will promptly take the actions directed by the Tennessee Court of Appeals and Endo will continue to seek a stay of further trial court proceedings including, if necessary, in the appellate courts.'

The Company also intends to seek review by the Tennessee Supreme Court of the trial court's order permitting the substitution of new plaintiffs in the case after the Tennessee Court of Appeals denied Endo's application for discretionary review of that order on June 8, 2021.

As originally filed, the Staubus case involved allegations by three Tennessee District Attorneys General and an individual plaintiff that Endo's sale of prescription opioid medications violated Tennessee's Drug Dealer Liability Act (the 'DDLA'). In December 2020, the Tennessee Supreme Court unanimously ruled that Tennessee's District Attorneys General lack standing to bring claims under the DDLA. On April 5, 2021, the trial court permitted several Tennessee towns, cities and counties to substitute into the case in place of the District Attorney General plaintiffs. The next day, on April 6, 2021, the trial court entered a default judgment order against Endo on liability as a sanction for alleged discovery improprieties. That order did not award any damages to the plaintiffs. The trial court has scheduled a trial on damages to begin on July 26, 2021.

About Endo International plc

Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Mr. Maletta and statements relating to the status and/or outcome of litigation. All forward-looking statements in this press release reflect Endo's current expectations of future events based on information available to Endo as of the date of this press release. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Endo's expectations and projections, including with respect to the impact of the Staubus case or any other litigation, investigation or settlement proceeding on our financial statements, including our cash flows from operations; our ability to adjust to changing market conditions; our ability to attract and retain key personnel; our ability to maintain compliance with our financial obligations under certain of our outstanding debt obligations, causing a downgrade of our debt and long-term corporate ratings (which could increase our cost of capital) and exposing us to potential events of default (if not cured or waived) under financial and operating covenants contained in our or our subsidiaries' outstanding indebtedness; our ability to incur additional borrowings under the covenants in our then-existing facilities or to obtain additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or general corporate or other purposes, or to refinance our indebtedness; and/or a significant reduction in our short-term and long-term revenues and/or otherwise cause us to be unable to fund our operations and liquidity needs, such as future capital expenditures and payment of our indebtedness. The occurrence or possibility of any such result may cause us to engage in a strategic review that ultimately results in our pursuing one or more significant corporate transactions or remedial measures. Other risks and uncertainties include general industry and market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; challenges related to product marketing, such as the unpredictability of market acceptance for new products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these and other risk factors can be found in Endo's periodic reports filed with the U.S. Securities and Exchange Commission and in Canada on the System for Electronic Data Analysis and Retrieval, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K.


Endo International plc


Heather Zoumas-Lubeski

T: (484) 216-6829

E: media.relations@endo.com


Pravesh Khandelwal

E: relations.investor@endo.com

(C) 2021 Electronic News Publishing, source ENP Newswire

07/22ENDO INTERNATIONAL : Reaches Agreement in Principle to Settle Opioid-Related Cas..
07/22ENDO INTERNATIONAL : Drugmaker Endo settles opioid claims by Tennessee counties,..
07/22ENDO INTERNATIONAL : Drugmaker Endo settles opioid claims by Tennessee counties,..
07/22ENDO INTERNATIONAL : Announces Agreement in Principle to Settle Tennessee State ..
07/21FACTBOX-Companies pay billions of dollars over role in U.S. opioid crisis
07/21Drugmakers, pharmacies next targets for U.S. opioid settlements
07/20New York, drug distributors reach $1.18 billion opioid settlement as national..
07/20MARKET CHATTER : Endo Pharmaceuticals Soars After Drug Maker Reportedly Proposes..
07/20SECTOR UPDATE : Health Care Stock Drifting Away From Earlier Highs This Afternoo..
07/20Endo international shares last up 31% at $4.40 in heavy volume
More news
Financials (USD)
Sales 2021 2 725 M - -
Net income 2021 122 M - -
Net Debt 2021 6 743 M - -
P/E ratio 2021 7,94x
Yield 2021 -
Capitalization 1 167 M 1 167 M -
EV / Sales 2021 2,90x
EV / Sales 2022 2,80x
Nbr of Employees 3 397
Free-Float 98,5%
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 5,00 $
Average target price 7,78 $
Spread / Average Target 55,6%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations